Profile data is unavailable for this security.
About the company
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
- Revenue in USD (TTM)0.00
- Net income in USD-38.68m
- Incorporated2021
- Employees163.00
- LocationProKidney Corp2000 Frontis Plaza Blvd., Suite 250WINSTON-SALEM 27103United StatesUSA
- Phone+1 (336) 999-7028
- Websitehttps://prokidney.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adaptive Biotechnologies Corp | 168.77m | -213.47m | 685.75m | 709.00 | -- | 2.84 | -- | 4.06 | -1.47 | -1.47 | 1.16 | 1.64 | 0.2501 | 4.74 | 5.03 | 238,033.80 | -31.65 | -19.69 | -36.63 | -22.06 | 54.77 | 67.18 | -126.55 | -122.27 | 3.84 | -- | 0.3536 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
Ironwood Pharmaceuticals, Inc. | 400.57m | 9.21m | 686.88m | 267.00 | 99.51 | -- | 74.49 | 1.71 | 0.0432 | 0.0432 | 2.43 | -2.01 | 0.8021 | -- | 4.52 | 1,500,244.00 | 1.44 | -4.54 | 2.21 | -5.20 | -- | -- | 1.79 | -7.81 | -- | 4.60 | 2.07 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Wave Life Sciences Ltd | 110.50m | -73.74m | 708.51m | 266.00 | -- | -- | -- | 6.41 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
ProKidney Corp | 0.00 | -38.68m | 712.60m | 163.00 | -- | -- | -- | -- | -0.5905 | -0.5905 | 0.00 | -7.73 | 0.00 | -- | -- | 0.00 | -27.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
Astria Therapeutics Inc | 0.00 | -93.24m | 713.78m | 59.00 | -- | 2.76 | -- | -- | -2.30 | -2.30 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -32.43 | -64.48 | -33.78 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
MBX Biosciences Inc | 0.00 | -47.20m | 718.30m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
Stoke Therapeutics Inc | 15.16m | -103.57m | 723.91m | 110.00 | -- | 2.96 | -- | 47.76 | -2.18 | -2.18 | 0.317 | 4.64 | 0.0537 | -- | 68.74 | 137,790.90 | -36.68 | -31.62 | -41.57 | -33.92 | -- | -- | -683.31 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
Savara Inc | 0.00 | -75.29m | 739.06m | 37.00 | -- | 6.10 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Annexon Inc | 0.00 | -115.16m | 742.75m | 71.00 | -- | 2.05 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Replimune Group Inc | 0.00 | -220.01m | 745.39m | 331.00 | -- | 1.75 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
Scholar Rock Holding Corp | 0.00 | -203.85m | 751.51m | 150.00 | -- | 5.62 | -- | -- | -2.22 | -2.22 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -79.66 | -38.14 | -89.70 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2726 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
Zenas Biopharma Inc | 50.00m | -54.76m | 756.06m | 114.00 | -- | -- | -- | 15.12 | -1.38 | -1.38 | 1.26 | 4.04 | -- | -- | -- | 595,238.10 | -- | -- | -- | -- | -- | -- | -109.51 | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
Arbutus Biopharma Corp | 10.06m | -77.09m | 758.90m | 73.00 | -- | 6.20 | -- | 75.43 | -0.4416 | -0.4416 | 0.0575 | 0.6488 | 0.0597 | -- | 4.59 | 137,821.90 | -45.77 | -52.62 | -53.21 | -58.11 | -- | -- | -766.20 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
AbCellera Biologics Inc | 33.06m | -153.30m | 763.18m | 586.00 | -- | 0.6870 | -- | 23.09 | -0.5254 | -0.5254 | 0.1133 | 3.77 | 0.0224 | -- | 0.808 | 56,407.85 | -10.39 | 6.08 | -11.11 | 6.67 | -- | -- | -463.77 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Holder | Shares | % Held |
---|---|---|
Morgan Stanley Investment Management, Inc.as of 31 Mar 2024 | 10.13m | 8.61% |
GBM Administradora de Activos, SA de CV SOSIas of 31 May 2024 | 5.88m | 5.00% |
Suvretta Capital Management LLCas of 31 Mar 2024 | 3.87m | 3.29% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.49m | 2.12% |
Bleichroeder LPas of 31 Mar 2024 | 2.00m | 1.70% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.76m | 1.50% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.09m | 0.93% |
Brown University Investment Officeas of 30 Jun 2024 | 1.00m | 0.85% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 942.60k | 0.80% |
Santander Private Banking Gestion SA SGIICas of 31 Dec 2023 | 770.09k | 0.65% |